Avstera Therapeutics
Avstera Therapeutics is a biotech company dedicated to addressing large disease burdens and unmet patient needs by leveraging cutting-edge immunological cell insights to develop novel therapeutics. Their focus includes immunological challenges in cancer, obesity, and cardiovascular indications, with a primary program involving a highly selective oral HDAC6 inhibitor (AVS100) for treating tough-to-treat cancers. They aim to offer revolutionary, easily administered solutions to improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Avstera Therapeutics
Philadelphia, Pennsylvania, United States, North America
Products
Orally bioavailable selective HDAC6 inhibitor (IND-cleared)
A highly selective, orally bioavailable HDAC6 inhibitor developed for treatment of locally advanced or metastatic solid tumors; demonstrated preclinical tumor growth reduction and potentiation of PD-1 blockade, with IND clearance to initiate Phase Ia/b studies.
Next-generation orally bioavailable HDAC6 inhibitor candidates (cardiometabolic focus)
Lead discovery and optimization of HDAC6 inhibitor series for cardiometabolic and cardioprotective indications, with plans to advance lead candidates into IND-enabling studies.
Myeloid discovery platform (differentiated immortalized progenitor cells)
A cell-based discovery product comprising transitionally immortalized human myeloid progenitors that can be differentiated into macrophages, dendritic cells, neutrophils, and other myeloid types for target discovery, functional screens, and cell therapy research.
Orally bioavailable selective HDAC6 inhibitor (IND-cleared)
A highly selective, orally bioavailable HDAC6 inhibitor developed for treatment of locally advanced or metastatic solid tumors; demonstrated preclinical tumor growth reduction and potentiation of PD-1 blockade, with IND clearance to initiate Phase Ia/b studies.
Next-generation orally bioavailable HDAC6 inhibitor candidates (cardiometabolic focus)
Lead discovery and optimization of HDAC6 inhibitor series for cardiometabolic and cardioprotective indications, with plans to advance lead candidates into IND-enabling studies.
Myeloid discovery platform (differentiated immortalized progenitor cells)
A cell-based discovery product comprising transitionally immortalized human myeloid progenitors that can be differentiated into macrophages, dendritic cells, neutrophils, and other myeloid types for target discovery, functional screens, and cell therapy research.
Services
Myeloid target discovery and validation platform
Platform service for discovery and validation of molecular targets in myeloid cells using differentiated cells derived from transitionally immortalized human myeloid progenitors.
Preclinical cell therapy development (macrophage-based)
Preclinical development services for macrophage-based cell therapy approaches, including ex vivo reprogramming and functional assessment in tumor models.
Myeloid target discovery and validation platform
Platform service for discovery and validation of molecular targets in myeloid cells using differentiated cells derived from transitionally immortalized human myeloid progenitors.
Preclinical cell therapy development (macrophage-based)
Preclinical development services for macrophage-based cell therapy approaches, including ex vivo reprogramming and functional assessment in tumor models.
Expertise Areas
- Immunomodulatory small-molecule therapeutics
- Myeloid cell biology and macrophage reprogramming
- Preclinical oncology and translational immunology
- IND-enabling preclinical development and regulatory submissions
Key Technologies
- Selective HDAC6 inhibition
- Oral small-molecule pharmacology
- Translational in vivo tumor models
- Macrophage polarization assays